Genetic mutations in human rectal cancers detected by targeted sequencing

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Colorectal cancer (CRC) presents a significant global health challenge with high mortality rates.
• Genetic mutations in key signaling pathways are fundamental drivers of CRC development and progression.
• Accurate identification of these mutations is critical for tailoring patient treatment strategies.

Purpose of the Study:

• To employ a semiconductor-based targeted DNA sequencing method for identifying genetic mutations in human rectal cancer samples.
• To analyze the frequency and spectrum of mutations in a cohort of 91 CRC patients.
• To evaluate the clinical utility of targeted gene sequencing for CRC patient management.

Main Methods:

• Utilized a semiconductor-based targeted DNA sequencing approach.
• Sequenced DNA from 91 human rectal cancer samples.
• Analyzed mutation data for common and combination mutations.

Main Results:

• Frequent mutations were observed in KRAS (58.2%), TP53 (28.6%), APC (16.5%), FBXW7 (9.9%), and PIK3CA (9.9%).
• Additional mutations in BRAF, CTNNB1, ERBB2, and SMAD4 were detected.
• 41.8% of samples harbored two or more mutations, with common combinations including KRAS/TP53 and KRAS/APC.

Conclusions:

• Targeted DNA sequencing effectively identifies prevalent mutations in colorectal cancer.
• The high frequency of specific mutations like KRAS and TP53 underscores their importance in CRC pathogenesis.
• Targeted gene sequencing offers potential advantages in sensitivity, cost, and time, aiding clinicians in personalized CRC therapy.